Ryuta Tanaka

Dr. Ryuta Tanaka

orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2012 in Brain and Development
Verified
Journal Article
Closed access
RTRyuta Tanaka
Ryuta Tanaka
NINobuaki Iwasaki
Nobuaki Iwasaki
MHMasaharu Hayashi
Masaharu Hayashi
JNJunko Nakayama
Junko Nakayama
TOTatsuyuki Ohto
Tatsuyuki Ohto
RSRyo Sumazaki
Ryo Sumazaki

10 July 2021 in Pediatrics International
Verified
Journal Article
Closed access
PDF file
RTRyuta Tanaka
Ryuta Tanaka
FFFujiko Fukushima
Fujiko Fukushima
KMKeiichi Motoyama
Keiichi Motoyama
CKChie Kobayashi
Chie Kobayashi
IIIsho Izumi
Isho Izumi

23 July 2025 in Life
Verified
Journal Article
Open access
PDF file
YAYuichi Abe
Yuichi Abe
THToshimitsu Hamasaki
Toshimitsu Hamasaki
JNJun Natsume
Jun Natsume
YMYukiko Mogami
Yukiko Mogami
KMKei Murayama
Kei Murayama
AOAkira Ohtake
Akira Ohtake
An explorative study was conducted to evaluate the efficacy and safety of 5-aminolevulinic acid hydrochloride combined with sodium ferrous citrate (SPP-004) in 10 pediatric patients with Leigh syndrome (LS) aged 3–24 months in 10 institutions between December 2014 and July 2019. The patients were randomized and allocated to the SPP-004 or placebo group for a 12-week double-blind period, followed by a 12-week open-label period with SPP-004 and then a long-term study of up to 180 weeks. The efficacy and safety were evaluated using the Newcastle Pediatric Mitochondrial Disease Scale (NPMDS) and adverse events (AEs), respectively. No significant differences were found between groups in NPMDS scores, but prolonged SPP-004 treatment stabilized or improved scores. During the initial double-blind phase, the serum lactate levels increased in the placebo group but not in the SPP-004 group. Over the period of prolonged treatment with SPP-004, the average serum lactate level gradually decreased to a normal level. One patient died due to heart failure, presumably due to an underlying disease. Overall, 7 out of 10 patients received SPP-004 without developing severe AEs until the termination of the long-term study. Given the severe symptoms and poor prognosis of pediatric LS, NPMDS scores were indicative of stabilization in pediatric LS patients treated with SPP-004.

1 May 2007
Verified
Journal Article
Closed access
NINobuaki Iwasaki
Nobuaki Iwasaki
HKHideyo Kinugasa
Hideyo Kinugasa
AWAkimitsu Watanabe
Akimitsu Watanabe
TKTomoko Katagiri
Tomoko Katagiri
RTRyuta Tanaka
Ryuta Tanaka
HSHideo Satoh
Hideo Satoh

1 November 2003
Verified
Journal Article
Closed access
OTOhto Tatsuyuki
Ohto Tatsuyuki
NINobuaki Iwasaki
Nobuaki Iwasaki
MTMiho Takahashi
Miho Takahashi
RTRyuta Tanaka
Ryuta Tanaka
KHKenzo Hamano
Kenzo Hamano
AMAkira Matsui
Akira Matsui